Annovis Bio (NYSE: ANVS) Makes Strides in Neurodegenerative Disease Research with New Patent Filing
Annovis Bio (ANVS) files new composition of matter patent for buntanetap, marking a significant milestone in the fight against neurodegenerative diseases.
This news matters as it signifies a major breakthrough in the research and development efforts to address the unmet medical needs related to Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions.